公开(公告)号：US10786578B2

公开(公告)日：2020-09-29

申请号：US15329818

申请日：2015-07-27

Applicant: Novartis AG

Inventor： Tinya Abrams ,  Steven Bruce Cohen ,  Dylan Daniel ,  Catrin Finner ,  Bernhard Hubert Geierstanger ,  Thomas Huber ,  William Mallet ,  Matthew John Meyer ,  Weijia Ou ,  Siew Ho Schleyer ,  Kathrin Ulrike Tissot-Daguette

IPC: A61K39/00 ,  A61K47/68 ,  C07K16/28 ,  A61K51/10 ,  A61K49/00 ,  A61P35/02 ,  A61K39/395

Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.

公开(公告)号：US10537561B2

公开(公告)日：2020-01-21

申请号：US15996945

申请日：2018-06-04

Applicant: Novartis AG ,  Sloan-Kettering Institute for Cancer Research

Inventor： Dylan Daniel ,  Johanna Joyce ,  James Sutton

IPC: A61K31/4439 ,  A61K31/175 ,  A61K31/4545 ,  A61K31/675 ,  A61K45/06 ,  C07D417/12 ,  C07D417/14 ,  A61K39/395

Abstract: The present invention provides a compound of formula I; wherein R1 is an alkyl pyrazole or an alkyl carboxamide, and R2 is a hydroxycycloalkyl; or a pharmaceutically acceptable salt thereof, and compositions containing these compounds, for use to treat a brain tumor, particularly glioblastoma. The invention provides effective treatment of a brain tumor and can be used by oral administration of a compound of Formula I as further described herein. The invention also provides a method to treat a subject having a brain tumor such as glioblastoma, wherein the method comprises administering to the subject an effective amount of a compound of Formula I. Gene signatures correlated with successful treatment using these methods are also disclosed.

公开(公告)号：US11833215B2

公开(公告)日：2023-12-05

申请号：US16893359

申请日：2020-06-04

Applicant: Novartis AG

Inventor： Tinya Abrams ,  Steven Bruce Cohen ,  Dylan Daniel ,  Catrin Finner ,  Bernhard Hubert Geierstanger ,  Thomas Huber ,  William Mallet ,  Matthew John Meyer ,  Weijia Ou ,  Siew Ho Schleyer ,  Kathrin Ulrike Tissot-Daguette

IPC: C07K16/00 ,  A61K39/00 ,  A61K47/68 ,  C07K16/28 ,  A61K51/10 ,  A61K49/00 ,  A61P35/02 ,  A61K39/395

CPC classification number: A61K47/6803 ,  A61K39/39558 ,  A61K47/6849 ,  A61K49/00 ,  A61K51/103 ,  A61K51/1093 ,  A61P35/02 ,  C07K16/2803 ,  A61K2039/505 ,  A61K2039/545 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/77 ,  C07K2317/92

Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.

公开(公告)号：US20190030013A1

公开(公告)日：2019-01-31

申请号：US15996945

申请日：2018-06-04

Applicant: Novartis AG ,  Sloan-Kettering Institute for Cancer Research

Inventor： Dylan Daniel ,  Johanna Joyce ,  James Sutton

IPC: A61K31/4439 ,  A61K39/395 ,  A61K31/675 ,  A61K31/4545 ,  C07D417/14 ,  C07D417/12 ,  A61K45/06 ,  A61K31/175

CPC classification number: A61K31/4439 ,  A61K31/175 ,  A61K31/4545 ,  A61K31/675 ,  A61K39/3955 ,  A61K45/06 ,  C07D417/12 ,  C07D417/14

Abstract: The present invention provides a compound of formula I; wherein R1 is an alkyl pyrazole or an alkyl carboxamide, and R2 is a hydroxycycloalkyl; or a pharmaceutically acceptable salt thereof, and compositions containing these compounds, for use to treat a brain tumor, particularly glioblastoma. The invention provides effective treatment of a brain tumor and can be used by oral administration of a compound of Formula I as further described herein. The invention also provides a method to treat a subject having a brain tumor such as glioblastoma, wherein the method comprises administering to the subject an effective amount of a compound of Formula I. Gene signatures correlated with successful treatment using these methods are also disclosed.